Literature DB >> 17460399

Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults.

David J Margolis1, Ole Hoffstad, Warren Bilker.   

Abstract

BACKGROUND: Two topical calcineurin inhibitors (TCI) are available for the treatment of atopic dermatitis and there has been concern that their use could be associated with an increased risk of nonmelanoma skin cancer (NMSC).
OBJECTIVE: To determine if TCI exposure is associated with an increased risk of NMSC in adults.
METHODS: A case-control study using a questionnaire mailed to 5,000 adults with dermatitis.
RESULTS: We received responses from 70.7% of those surveyed by mail. Overall, 25.7% reported exposure to TCI. TCI exposure was 14.4% for the cases and 30.7% for the controls. Our primary analysis was a comparison between those with NMSC and those without. The unadjusted odds ratio was 0.38 (0.31-0.47) and the adjusted (age, gender, previous NMSC, history of atopic dermatitis) was 0.54 (0.41-0.69). The odds ratio of association for NMSC decreased as the number of tubes used and the potency of the agent increased.
CONCLUSION: This early study shows that TCI use is not associated with an increased risk of NMSC in adults. 2007 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17460399     DOI: 10.1159/000100879

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  16 in total

Review 1.  How I treat refractory chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Adela R Cardones; Keith M Sullivan
Journal:  Blood       Date:  2019-01-23       Impact factor: 22.113

2.  Risk of squamous cell carcinoma of the skin in relation to IgE: a nested case-control study.

Authors:  Joseph L Wiemels; John K Wiencke; Zhongze Li; Christian Ramos; Heather H Nelson; Margaret R Karagas
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-09-23       Impact factor: 4.254

3.  Guidelines for the management of atopic dermatitis (eczema) for pharmacists.

Authors:  Ian T Y Wong; Ross T Tsuyuki; Amanda Cresswell-Melville; Philip Doiron; Aaron M Drucker
Journal:  Can Pharm J (Ott)       Date:  2017-05-30

4.  Atopic dermatitis.

Authors:  Thomas Bieber
Journal:  Ann Dermatol       Date:  2010-05-17       Impact factor: 1.444

5.  Filaggrin sequencing and bioinformatics tools.

Authors:  David J Margolis; Nandita Mitra; Bradley Wubbenhorst; Katherine L Nathanson
Journal:  Arch Dermatol Res       Date:  2019-08-01       Impact factor: 3.017

Review 6.  Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice.

Authors:  Elaine C Siegfried; Jennifer C Jaworski; Adelaide A Hebert
Journal:  Am J Clin Dermatol       Date:  2013-06       Impact factor: 7.403

Review 7.  [New and rarley used treatment options for refractory hand eczema: local UVA-1 phototherapy, retinoids, calcineurin inhibitors].

Authors:  U Raap; C Kenneweg; A Kapp; T Werfel
Journal:  Hautarzt       Date:  2008-09       Impact factor: 0.751

Review 8.  Topical pimecrolimus: a review of its use in the management of pediatric atopic dermatitis.

Authors:  Lily P H Yang; Monique P Curran
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 9.  [Topical therapy for atopic eczema].

Authors:  M Knop; A Gürtler; A Heratizadeh; N Aszodi; Th Werfel; A Wollenberg
Journal:  Hautarzt       Date:  2018-03       Impact factor: 0.751

Review 10.  The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy.

Authors:  Johannes Ring; Matthias Möhrenschlager; Verena Henkel
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.